Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Status:
Completed
Trial end date:
2020-05-18
Target enrollment:
Participant gender:
Summary
This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a
small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer
cells, in patients with advanced malignancies. As of March 1, 2019, only patients with
neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on
days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will
be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues
until disease progression, unacceptable toxicity, physician discretion, or patient refusal.